Breaking News Instant updates and real-time market news.

GILD

Gilead

$80.38

2.01 (2.56%)

14:25
02/07/18
02/07
14:25
02/07/18
14:25

Gilead announces FDA approval of Biktarvy combo treatment for HIV-1 infection

Gilead Sciences announced that the U.S. Food and Drug Administration has approved Biktarvy, a once-daily single tablet regimen for the treatment of HIV-1 infection. Biktarvy combines the novel, unboosted integrase strand transfer inhibitor bictegravir, with the demonstrated safety and efficacy profile of the Descovy dual nucleoside reverse transcriptase inhibitor backbone, and is the smallest INSTI-based triple-therapy STR available, the company stated. Biktarvy has a Boxed Warning in its product label regarding the risk of post treatment acute exacerbation of hepatitis B. Additional clinical trials of Biktarvy are ongoing, including a dedicated study in women, as well as a study in adolescents and children living with HIV. Gilead plans to present data from these studies at scientific conferences in 2018.

  • 12

    Feb

GILD Gilead
$80.38

2.01 (2.56%)

01/30/18
SBSH
01/30/18
UPGRADE
Target $103
SBSH
Buy
Citi upgrades Gilead to Buy with $103 target following tax reform
Citi analyst Robyn Karnauskas upgraded Gilead Sciences to Buy from Neutral and raised her price target for the shares to $103 from $81. The drugmaker closed yesterday up $3.34 to $88.80. Tax reform could lower the company's tax rate to 22% in 2018 versus prior estimates of 28%, Karnauskas tells investors in a research note. The analyst also raised her nonalcoholic steatohepatitis and JAK-1 probability of success estimates to 50% with both Phase 3 trials expected in the next 12 months. Further, Karnauskas expects Gilead's hepatitis C virus business to stabilize by mid-2018.
01/30/18
01/30/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CVS Health (CVS) upgraded to Strong Buy from Buy at Needham by analyst Kevin Caliendo, who contended that the stock remains underowned and, unlike its peers, yet to rally beyond the expectations of benefits from the tax changes. The analyst says the company's multiple has remained constant despite the expansion in the rest of the pharma services industry, forecasting EPS growth of 8%-10% beyond the modeled $8 per share in 2019. 2. JetBlue (JBLU) upgraded to Overweight from Neutral at JPMorgan by analyst Jamie Bakier who said the company's costs are "gradually coming under control" and its balance sheet is "sound." The analyst also upgraded United Continental (UAL) to Overweight from Underweight, saying the shares are the "cheapest in the sector and among the most washed out, having declined the most from recent highs." 3. Gilead (GILD) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who said that tax reform could lower the company's tax rate to 22% in 2018 versus prior estimates of 28%. The analyst also raised her nonalcoholic steatohepatitis and JAK-1 probability of success estimates to 50% with both Phase 3 trials expected in the next 12 months. Further, Karnauskas expects Gilead's hepatitis C virus business to stabilize by mid-2018. 4. Intel (INTC) upgraded to Buy from Neutral at Citi by analyst Christopher Danely, who said overly conservative guidance and poor sentiment from years of underperformance should drive estimates and the stock higher in the near term. He believes management's "new habit" of conservative guidance is good for the stock. 5. Albemarle (ALB) upgraded to Buy from Neutral at UBS by analyst John Roberts, who said the stock is down 23% from the November high despite no change to the outlook for lithium. The analyst attributes the pullback to larger scale lithium expansion announcements and raising concerns of potential oversupply. He believes the market is pricing in 10% annual realized price declines for Albemarle over the next few years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/31/18
JEFF
01/31/18
NO CHANGE
JEFF
Jefferies sees neutral impact on Biotech from State of the Union
Jefferies analyst Michael Yee sees a net neutral impact on Biotech stocks from President Trump's State of the Union speech last night. During the speech, Trump made comments about making lower drug prices a "priority" for the year, Yee tells investors in a research not titled "Drug Pricing Comments Not New or Surprising - But a Reminder of Rhetoric." The President, however, also commented on broader access to novel clinical trial drugs, Yee points out. After a "strong biotech rally" in January, the analyst assumes the sector, "at some point," will have some relative near-term pullback either on uncertainty about Trump commentary or some consolidation. Some of the analyst's Buy-rated names include AbbVie (ABBV), Amgen (AMGN), Eli Lilly (LLY) and Gilead Sciences (GILD).
02/07/18
SBSH
02/07/18
NO CHANGE
Target $105
SBSH
Buy
Gilead should be bought ahead of pipeline catalysts, says Citi
Citi analyst Robyn Karnauskas raised her price target for Gilead Sciences to $105 from $103 following last night's Q4 results. The analyst recommends buying the stock ahead of pipeline catalysts and keeps a Buy rating on the name. The base business seems to be stabilizing while gene therapy could be a potential growth area, Karnauskas tells investors in a post-earnings research note.

TODAY'S FREE FLY STORIES

04:55
06/22/18
06/22
04:55
06/22/18
04:55
General news
PMI Composite Flash â€' Level to be reported at 09:45 »

June PMI Composite Flash…

QGEN

Qiagen

$36.20

-0.23 (-0.63%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Qiagen participates in a conference call with William Blair »

CFO Sachers participates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

04:55
06/22/18
06/22
04:55
06/22/18
04:55
General news
PMI Composite Flash Manufacturing â€' Level to be reported at 09:45 »

June PMI Composite Flash…

AOBC

American Outdoor Brands

$12.80

-0.42 (-3.18%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
American Outdoor Brands management to meet with Wedbush »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

NGVT

Ingevity

$82.89

-0.12 (-0.14%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Ingevity management to meet with Loop Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SBUX

Starbucks

$50.62

-1.6 (-3.06%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Starbucks management to meet with Wedbush »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 10

    Jul

AMGN

Amgen

$186.00

-0.51 (-0.27%)

, ARRY

Array BioPharma

$19.56

-0.43 (-2.15%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO World Congress on…

AMGN

Amgen

$186.00

-0.51 (-0.27%)

ARRY

Array BioPharma

$19.56

-0.43 (-2.15%)

BAYRY

Bayer

$0.00

(0.00%)

HALO

Halozyme

$18.59

-0.88 (-4.52%)

INCY

Incyte

$72.47

-0.97 (-1.32%)

LLY

Eli Lilly

$86.07

-0.17 (-0.20%)

MRK

Merck

$61.17

-0.125 (-0.20%)

SHPG

Shire

$162.43

1.81 (1.13%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$39.02

-0.38 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 23

    Jun

  • 28

    Jun

  • 30

    Jun

  • 30

    Jun

  • 10

    Sep

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 21

    Dec

  • 28

    Jan

  • 22

    Mar

TAC

TransAlta

$4.95

(0.00%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
TransAlta management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

NUVA

NuVasive

$55.48

-1.18 (-2.08%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
NuVasive has a conference call hosted by JPMorgan »

JPMorgan Analyst Marcus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

HUBG

Hub Group

$53.05

-0.8 (-1.49%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Hub Group management to meet with Loop Capital »

Field trip to company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

PVAC

Penn Virginia

$79.38

-1.7 (-2.10%)

, ALOG

Analogic

$83.98

0.025 (0.03%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Hot Stocks
Penn Virginia to replace Analogic in S&P 600 at open on June 22 »

Altaris Capital Partners…

PVAC

Penn Virginia

$79.38

-1.7 (-2.10%)

ALOG

Analogic

$83.98

0.025 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLR

Fluor

$48.68

-1.035 (-2.08%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Fluor management to meet with MKM Partners »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Macquarie to hold a summit »

Emerging Industries…

INST

Instructure

$45.00

-1.675 (-3.59%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Instructure management to meet with Needham »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 26

    Jun

RLH

Red Lion Hotels

$11.70

-0.15 (-1.27%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Red Lion Hotels management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Stephens food/agribusiness analyst to hold an analyst/industry conference call »

Food & Agribusiness…

04:55
06/22/18
06/22
04:55
06/22/18
04:55
General news
Breaking General news story  »

Week of 6/22 Baker-Hughes…

NUVA

NuVasive

$55.48

-1.18 (-2.08%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
NuVasive management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

IRTC

iRhythm

$79.00

-1.67 (-2.07%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
iRhythm management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

EURN

Euronav NV

$9.80

0.1 (1.03%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Euronav NV management to meet with Seaport Global »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

PRMW

Primo Water

$17.78

0.02 (0.11%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Primo Water management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SWN

Southwestern Energy

$5.27

-0.105 (-1.95%)

04:54
06/22/18
06/22
04:54
06/22/18
04:54
Recommendations
Southwestern Energy analyst commentary  »

Southwestern Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

AMSWA

American Software

$14.94

-0.21 (-1.39%)

04:52
06/22/18
06/22
04:52
06/22/18
04:52
Recommendations
American Software analyst commentary  »

American Software price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

02:10
06/22/18
06/22
02:10
06/22/18
02:10
General news
OPEC and allies, reached preliminary deal on output »

OPEC and allies, reached…

02:00
06/22/18
06/22
02:00
06/22/18
02:00
General news
Asian Market Wrap: »

Asian Market Wrap:…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.